Prostaglandin E2 levels in cerebrospinal fluid of normal and narcoleptic dogs.
It has been shown that endogenous prostaglandin D2 and prostaglandin E2 (PGE2) are involved in sleep-wake regulation. Our recent experimental result that exogenously administered PGE2 significantly reduces canine cataplexy (a pathological equivalent of rapid-eye-movement sleep atonia and a symptom of narcolepsy) suggests that PGE2 is involved in the pathophysiology of canine narcolepsy. In order to further investigate the role of prostaglandins (PGs) in this disorder, PG levels in cerebrospinal fluid (CSF) of genetically homozygous narcoleptic, heterozygous (unaffected), and control Doberman pinschers were studied. PGE2 levels were measured by direct radioimmunoassay (RIA) and after high-grade purification using PG affinity columns and high-performance liquid chromatography. PGD2 and PGF2 alpha levels were measured by RIA after high-grade purification. There was no significant difference in PGE2 levels between homozygous narcoleptic and heterozygous or controls dogs, and PGD2 and PGF2 alpha levels were undetectable in most cases. Our results do not favor the hypothesis that central PGE2 levels are modified in canine narcolepsy, assuming that PGE2 levels in cisternal CSF properly reflect PGE2 production in the brain.
Nishino
S
S
Sleep Disorders Center, Stanford University School of Medicine, Palo Alto, CA 94304.
Mignot
E
E
Kilduff
T S
TS
Sakai
T
T
Hayaishi
O
O
Dement
W C
WC
D000818:Animals; D015237:Dinoprost / Q000134:cerebrospinal fluid; D015232:Dinoprostone / Q000134:cerebrospinal fluid*; D004283:Dog Diseases / Q000134:cerebrospinal fluid* / Q000235:genetics; D004285:Dogs; D005260:Female; D006580:Genetic Carrier Screening; D008297:Male; D009290:Narcolepsy / Q000134:cerebrospinal fluid / Q000235:genetics / Q000662:veterinary*; D015230:Prostaglandin D2 / Q000134:cerebrospinal fluid
D015237:Dinoprost; D015232:Dinoprostone; D015230:Prostaglandin D2